The NCCN recommends amivantamab-vmjw or mobocertinib for treatment of advanced or metastatic NSCLC that carries an EGFR exon 20 insertion in patients who have progressed after first line treatment, with pembrolizumab plus platinum-based chemotherapy as the preferred first line option. The other agents are directed at different driver mutations in advanced NSCLC, including capmatinib, which targets MET exon 14 skipping mutations, larotrectinib, which targets NTRK1/2/3 fusions, and pralsetinib, which targets RET fusions.

References:
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. Updated April 13, 2023. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450